Powder: -20°C for 3 years | In solvent: -80°C for 2 years
ULK-101 是一种选择性 ULK1抑制剂，可抑制自噬，对 ULK1和 ULK2 的 IC50值分别为 8.3 nM 和 30 nM。
| 产品描述 | ULK-101 is a potent and selective ULK1 inhibitor ( IC50s: 8.3/30 nM for ULK1/ULK2). It can suppress autophagy. |
| 靶点活性 | ULK2:30 nM (cell free), ULK1:8.3 nM (cell free) |
| 体外活性 | U2OS cells were treated with AZD8055 for 2.5 hr, a catalytic mTOR inhibitor that strongly induces autophagy in U2OS cells and observed that the abundance of DFCP1-positive puncta increased over 3-fold. Co-treatment of cells with 5 μM ULK-101 completely abrogated the formation of DFCP1-positive structures induced by AZD8055 treatment, consistent with the loss of Beclin 1 phosphorylation. |
| 激酶实验 | IC50 data for ULK1 and ULK2 was generated using 10-point IC50Profiler assays with half-log dilutions from top concentrations of 10 μM (4 replicates) and 1 μM (4 replicates), giving 8 data points for most concentrations in the curve. For selectivity profiling, KinaseProfiler assays with wild-type human kinase panels were performed in duplicate using 500 nM SBI-0206965, 40 nM ULK-101, or 15 nM ULK-100. For each kinase reaction, the Km concentration of ATP was used. The percent activity remaining and percent inhibition were calculated from negative control wells. For selectivity profiling, relative inhibition was calculated by dividing the percent inhibition of each kinase by the percent inhibition of ULK1. GraphPad Prism 7 was used for IC50 determinations by fitting curves with variable slope (four-parameter) non-linear regression models using top and bottom constraints of 100% and 0%, respectively. |
| 细胞实验 | Cells (U2OS or NSCLC) were seeded on tissue culture treated 96-well plates at 1,000 cells per well in RPMI-1640 media supplemented with 10% FBS. Twenty-four hours later, media was aspirated, wells rinsed with 1x DPBS, and replaced with full media (FM) or Optistarve (OS) with a concentration gradient of ULK-101 (final concentrations of 100 μM, 50 μM, 25 μM, 12.5 μM, 6.25 μM, 3.1 μM, 1.6 μM, 0.8 μM, 0.4 μM, or 0 μM). Two days later, media (and ULK-101) was aspirated, wells were rinsed with 1x DPBS, and all wells replaced with FM. Five days later, relative ATP levels were measured using a luminescent CellTiter-Glo assay. |
| 分子量 | 460.45 |
| 分子式 | C22H16F4N4OS |
| CAS No. | 2443816-45-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
DMSO: 80 mg/mL (173.74 mM)
H2O: Insoluble
( < 1 mg/mL refers to the product slightly soluble or insoluble )
参考文献文献引用
剂量换算对于不同动物的给药剂量换算，您也可以参考 更多...
体内实验配液计算器请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法： 比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)， 如您需要配置的浓度超过该产品的溶解度，请先与我们联系。
体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300， 混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。
计算器bottom
您可能有的问题的答案可以在抑制剂处理说明中找到，包括如何准备库存溶液，如何存储产品，以及基于细胞的分析和动物实验需要特别注意的问题。
ULK-101 2443816-45-1 Autophagy Unc-51 like kinase ULK ULK 101 Inhibitor ULK101 inhibit inhibitor
沪公网安备 31010602006700号
